{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:26:49Z","timestamp":1778758009111,"version":"3.51.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"abstract":"<jats:p>Although protamine induces cardiotoxicity, ulinastatin has been shown to attenuate protamine-induced cardiotoxicity in rats. However, whether ulinastatin alleviates protamine-induced cardiac depression during cardiac surgery remains unclear. This study aimed to evaluate the degree of protamine-induced hypotension in patients undergoing cardiac surgery who received ulinastatin.<\/jats:p>\n                  <jats:p>This post hoc exploratory analysis included patients undergoing scheduled cardiac surgery. Patients were divided into 2 groups: ulinastatin and control. Patients in the ulinastatin group received 300,000 U of ulinastatin before cardiopulmonary bypass, while those in the control group did not receive ulinastatin. Propensity score matching was performed. Arterial blood pressure (ABP), pulmonary artery pressure, continuous cardiac index, systemic vascular resistance index, and vasopressor use were recorded. The primary outcome was the change in mean ABP after protamine administration.<\/jats:p>\n                  <jats:p>\n                    After propensity score matching, 30 patients were included in each of the control and ulinastatin groups. Patient characteristics were comparable between the 2 groups. The protamine-induced decrease in mean ABP was significantly lower in the ulinastatin group than in the control group (4 [0\u20139] vs 8 [4\u201313] mm Hg, median [interquartile range],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.015). There were no significant differences in pulmonary artery pressure and vasopressor use between the groups. While the continuous cardiac index was comparable between the groups after protamine administration, systemic vascular resistance index was significantly higher in the ulinastatin group than in the control group (2090.1 [342.5] vs 1616.2 [644.4] dynes*sec\/cm\n                    <jats:sup>5<\/jats:sup>\n                    \/m\n                    <jats:sup>2<\/jats:sup>\n                    , mean [standard deviation],\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.022).\n                  <\/jats:p>\n                  <jats:p>Ulinastatin mitigates protamine-induced hypotension, maintaining systemic vascular resistance.<\/jats:p>","DOI":"10.1097\/md.0000000000045545","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:02:48Z","timestamp":1764169368000},"page":"e45545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ulinastatin mitigates protamine-induced hypotension during cardiac surgery: A retrospective observational study using propensity score matching"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5772","authenticated-orcid":false,"given":"Keisuke","family":"Omiya","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of Yamanashi, Chuo, Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nakadate","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Tsukuba, Tsukuba, Ibaraki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Oguchi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Yamanashi, Chuo, Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Yamanashi, Chuo, Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jtha.2023.04.005","article-title":"What\u2019s fishy about protamine? Clinical use, adverse reactions, and potential alternatives.","volume":"21","author":"Levy","year":"2023","journal-title":"J Thromb Haemost"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00000542-200112000-00018","article-title":"Protamine-induced cardiotoxicity is prevented by anti-TNF-alpha antibodies and heparin.","volume":"95","author":"Pevni","year":"2001","journal-title":"Anesthesiology"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00000542-199111000-00016","article-title":"Effects of protamine on vascular smooth muscle of rabbit mesenteric artery.","volume":"75","author":"Akata","year":"1991","journal-title":"Anesthesiology"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1213\/00000539-198901000-00007","article-title":"Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs.","volume":"68","author":"Conzen","year":"1989","journal-title":"Anesth Analg"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00210-020-01983-2","article-title":"Ulinastatin attenuates protamine-induced cardiotoxicity in rats by inhibiting tumor necrosis factor alpha.","volume":"394","author":"Fukushima","year":"2021","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1053-0770(05)80124-7","article-title":"Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions.","volume":"9","author":"Baraka","year":"1995","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.burns.2007.08.024","article-title":"Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns.","volume":"34","author":"Huang","year":"2008","journal-title":"Burns"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.jvca.2012.11.001","article-title":"Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest.","volume":"27","author":"Xu","year":"2013","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/00000542-200106000-00016","article-title":"Role of heparin and nitric oxide in the cardiac and regional hemodynamic properties of protamine in conscious chronically instrumented dogs.","volume":"94","author":"Oguchi","year":"2001","journal-title":"Anesthesiology"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3892\/ijmm.2013.1322","article-title":"Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor\u2011\u03baB in BV2 mouse microglial cells.","volume":"31","author":"Sung","year":"2013","journal-title":"Int J Mol Med"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"630835","DOI":"10.1155\/2014\/630835","article-title":"Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.","volume":"2014","author":"He","year":"2014","journal-title":"Biomed Res Int"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00059-018-4732-0","article-title":"Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials.","volume":"45","author":"He","year":"2020","journal-title":"Herz"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jclinane.2005.05.008","article-title":"Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy.","volume":"18","author":"Kurosawa","year":"2006","journal-title":"J Clin Anesth"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ejcts.2004.07.044","article-title":"The effect of methylprednisolone treatment on the cardiopulmonary bypass-induced systemic inflammatory response.","volume":"26","author":"Bourbon","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1253\/jcj.59.815","article-title":"Beneficial effect of steroid on myocardial preservation in isolated rat hearts.","volume":"59","author":"Hisatomi","year":"1995","journal-title":"Jpn Circ J"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10715760000300591","article-title":"Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage.","volume":"33","author":"Valen","year":"2000","journal-title":"Free Radic Res"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(15)00273-1","article-title":"Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.","volume":"386","author":"Whitlock","year":"2015","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:06:48Z","timestamp":1778756808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":18,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045545","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-04-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}